UK starts L50m initiative for personalised medicine
London - The UK's Technology Strategy Board launched the Stratified Medicines Innovation Platform to provide over L50 million for personalized medicines research over the next five years. The platform will bring together researchers, policymakers and the private sector in an initiative for research and development in areas such as tumour profiling to improve cancer care and biomarker development to enhance drug effectiveness.
The first three funding competitions will provide up to L5.6 million ($8.9 million) for tumor profiling and for IT to collect and store tumor data; up to L4 million ($6.4 million) for identifying inflammation biomarkers; and up to L1.5 ($2.4) million for business models to enable drug and diagnostics companies to work together to develop drugs and companion diagnostics. Applications open in January 2011.
The Platform is a five-year partnership programme that will develop a series of activities at national level to address the challenges of stratification for the benefit of business, healthcare providers and the wider economy.
The BioIndustry Association also welcomed the initiative, pointing out that establishing a stratified disease strategy was one of the recommendations in the Review and Refresh of Bioscience 2015, an independent report published in January 2009 by the Bioscience Innovation and Growth Team.